Barclays PLC Acquires 5,353 Shares of Q32 Bio Inc. (NASDAQ:QTTB)

Barclays PLC grew its holdings in Q32 Bio Inc. (NASDAQ:QTTB) by 105.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,443 shares of the company’s stock after acquiring an additional 5,353 shares during the period. Barclays PLC owned 0.09% of Q32 Bio worth $465,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Values First Advisors Inc. purchased a new stake in shares of Q32 Bio in the 3rd quarter worth $33,000. BNP Paribas Financial Markets grew its holdings in Q32 Bio by 199.1% during the third quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock valued at $58,000 after purchasing an additional 864 shares during the period. Rhumbline Advisers increased its position in Q32 Bio by 11,681.5% in the second quarter. Rhumbline Advisers now owns 7,658 shares of the company’s stock worth $137,000 after buying an additional 7,593 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of Q32 Bio in the third quarter worth about $159,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Q32 Bio during the 2nd quarter valued at about $265,000. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Wall Street Analysts Forecast Growth

QTTB has been the subject of several analyst reports. Oppenheimer reduced their target price on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Wells Fargo & Company reissued an “equal weight” rating and issued a $16.00 price objective (down from $95.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Piper Sandler decreased their price objective on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Guggenheim downgraded shares of Q32 Bio from a “buy” rating to a “neutral” rating in a report on Wednesday, December 11th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.86.

Q32 Bio Trading Up 4.5 %

Shares of Q32 Bio stock opened at $3.28 on Friday. Q32 Bio Inc. has a twelve month low of $2.99 and a twelve month high of $53.79. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61. The business has a 50-day moving average price of $15.60 and a 200-day moving average price of $31.28. The firm has a market cap of $39.95 million, a price-to-earnings ratio of -0.23 and a beta of -0.30.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.